{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:09:50Z","timestamp":1786727390934,"version":"build-2736575974"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004621","name":"Kerman University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-11106-w","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T06:43:33Z","timestamp":1760424213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Zataria multiflora extract enhances imatinib-induced cytotoxicity in chronic myeloid leukemia and multiple myeloma cells"],"prefix":"10.1007","volume":"52","author":[{"given":"Sahar","family":"Mostajeran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Ehsan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahla","family":"Lashkari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajar Mardani","family":"Valandani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Fatemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Bazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdieh","family":"Mirzaie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hossein","family":"Ashoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roohollah Mirzaee","family":"Khalilabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"11106_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Kantarjian H (2025) Chronic myeloid leukemia: a review. JAMA. https:\/\/doi.org\/10.1001\/jama.2025.0220","journal-title":"JAMA"},{"key":"11106_CR2","doi-asserted-by":"publisher","first-page":"155161","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Nsairat H, Matalka II, Lee YF, Rizzo M, Aljabali AA et al (2024) The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia. Pathology-Research Pract 254:155161","journal-title":"Pathology-Research Pract"},{"key":"11106_CR3","doi-asserted-by":"publisher","unstructured":"\u00c7ift\u00e7iler R, Haznedaroglu I (2021) Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci. https:\/\/doi.org\/10.26355\/eurrev_202112_27625","DOI":"10.26355\/eurrev_202112_27625"},{"key":"11106_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1172910","volume":"13","author":"F Cheng","year":"2023","unstructured":"Cheng F, Yuan G, Li Q, Cui Z, Li W (2023) Long-term outcomes of frontline Imatinib therapy for chronic myeloid leukemia in China. Front Oncol 13:1172910","journal-title":"Front Oncol"},{"issue":"9","key":"11106_CR5","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1182\/blood.2024026311","volume":"145","author":"F Guilhot","year":"2025","unstructured":"Guilhot F, Hehlmann R (2025) Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia. Blood 145(9):910\u2013920","journal-title":"Blood"},{"issue":"1","key":"11106_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01544-7","volume":"22","author":"J Du","year":"2024","unstructured":"Du J, Lin Z, Fu X-H, Gu X-R, Lu G, Hou J (2024) Research progress of the chemokine\/chemokine receptor axes in the oncobiology of multiple myeloma (MM). Cell Commun Signal 22(1):177","journal-title":"Cell Commun Signal"},{"issue":"2","key":"11106_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/ijmm.2025.5623","volume":"55","author":"R Xing","year":"2025","unstructured":"Xing R, Wang M, Wang L, Pan M, Wang Y, Zhou H (2025) Clinical updates of B\u2013cell maturation antigen\u2013targeted therapy in multiple myeloma (MM) and relapsed\/refractory MM. Int J Mol Med 55(2):1\u201313","journal-title":"Int J Mol Med"},{"issue":"1","key":"11106_CR8","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41408-024-01115-6","volume":"14","author":"M Mohty","year":"2024","unstructured":"Mohty M, Facon T, Malard F, Harousseau J-L (2024) A roadmap towards improving outcomes in multiple myeloma. Blood Cancer J 14(1):135","journal-title":"Blood Cancer J"},{"key":"11106_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2020.112865","volume":"257","author":"M Azadi","year":"2020","unstructured":"Azadi M, Jamali T, Kianmehr Z, Kavoosi G, Ardestani SK (2020) In-vitro (2D and 3D cultures) and in-vivo cytotoxic properties of Zataria multiflora essential oil (ZEO) emulsion in breast and cervical cancer cells along with the investigation of Immunomodulatory potential. J Ethnopharmacol 257:112865","journal-title":"J Ethnopharmacol"},{"issue":"1","key":"11106_CR10","first-page":"141","volume":"24","author":"MS Ardestani","year":"2022","unstructured":"Ardestani MS (2022) Anti-cancer effects of nanoliposomes containing Rosemary and Zataria multiflora Boiss essential oils on HepG2 cell line under in vitro conditions. J Babol Univ Med Sci 24(1):141\u2013150","journal-title":"J Babol Univ Med Sci"},{"issue":"11","key":"11106_CR11","doi-asserted-by":"publisher","first-page":"451","DOI":"10.4103\/2221-1691.389570","volume":"13","author":"R Nosratabadi","year":"2023","unstructured":"Nosratabadi R, Anaeigoudari F, Anaeigoudari A (2023) Therapeutic potential of Zataria multiflora: a narrative review of current evidence. Asian Pac J Trop Biomed 13(11):451\u2013459","journal-title":"Asian Pac J Trop Biomed"},{"key":"11106_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.genrep.2020.100655","volume":"20","author":"H Anani","year":"2020","unstructured":"Anani H, Baluchi I, Farsinejad A, Fatemi A, Khalilabadi RM (2020) Zataria multiflora methanolic extract has antitumor properties on U266 multiple myeloma cell line. Gene Rep 20:100655","journal-title":"Gene Rep"},{"key":"11106_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40360-021-00523-9","volume":"22","author":"A Valizadeh","year":"2021","unstructured":"Valizadeh A, Khaleghi AA, Roozitalab G, Osanloo M (2021) High anticancer efficacy of solid lipid nanoparticles containing Zataria multiflora essential oil against breast cancer and melanoma cell lines. BMC Pharmacol Toxicol 22:1\u20137","journal-title":"BMC Pharmacol Toxicol"},{"key":"11106_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctcp.2020.101286","volume":"42","author":"E Zare","year":"2021","unstructured":"Zare E, Jamali T, Ardestani SK, Kavoosi G (2021) Synergistic effect of Zataria multiflora essential oil on doxorubicin-induced growth inhibition of PC3 cancer cells and apoptosis. Complement Ther Clin Pract 42:101286","journal-title":"Complement Ther Clin Pract"},{"issue":"19","key":"11106_CR15","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1111\/jcmm.17936","volume":"27","author":"A Memarzia","year":"2023","unstructured":"Memarzia A, Saadat S, Asgharzadeh F, Behrouz S, Folkerts G, Boskabady MH (2023) Therapeutic effects of medicinal plants and their constituents on lung cancer, in vitro, in vivo and clinical evidence. J Cell Mol Med 27(19):2841\u20132863","journal-title":"J Cell Mol Med"},{"issue":"1","key":"11106_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.32598\/Immunoregulation.6.1.6","volume":"6","author":"T Jamali","year":"2024","unstructured":"Jamali T, Kaboudanian Ardestani S (2024) Investigating anti-cancer, anti-oxidant and immunomodulatory effects of essential oils: focusing on Oliveria decumbens and Zataria multiflora essential oils. Immunoregulation 6(1):13\u201328","journal-title":"Immunoregulation"},{"issue":"11","key":"11106_CR17","doi-asserted-by":"publisher","first-page":"8259","DOI":"10.1007\/s00210-024-03196-3","volume":"397","author":"J Herrera-Bravo","year":"2024","unstructured":"Herrera-Bravo J, Bel\u00e9n LH, Reyes ME, Silva V, Fuentealba S, Paz C et al (2024) Thymol as adjuvant in oncology: molecular mechanisms, therapeutic potentials, and prospects for integration in cancer management. Naunyn Schmiedebergs Arch Pharmacol 397(11):8259\u20138284","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"11106_CR18","doi-asserted-by":"publisher","first-page":"12657","DOI":"10.1038\/s41598-022-16943-4","volume":"12","author":"M Lashkari","year":"2022","unstructured":"Lashkari M, Fatemi A, Valandani HM, Khalilabadi RM (2022) Promising anti-leukemic effect of Zataria multiflora extract in combination with doxorubicin to combat acute lymphoblastic leukemia cells (Nalm-6)(in vitro and in silico). Sci Rep 12(1):12657","journal-title":"Sci Rep"},{"issue":"5","key":"11106_CR19","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3109\/13880209.2015.1079223","volume":"54","author":"E Saedi Dezaki","year":"2016","unstructured":"Saedi Dezaki E, Mahmoudvand H, Sharififar F, Fallahi S, Monzote L, Ezatkhah F (2016) Chemical composition along with anti-leishmanial and cytotoxic activity of Zataria multiflora. Pharm Biol 54(5):752\u2013758","journal-title":"Pharm Biol"},{"key":"11106_CR20","doi-asserted-by":"crossref","unstructured":"Ashoub MH, Golestani A, Amiri M, Razavi R, Farsinejad A (2025) Ph-sensitive sulfasalazine release from green-synthesized mesoporous Fe3O4@ SiO2 nanocomposites using opuntia ficus-indica extract. J Pharm Sci 114(7):103792","DOI":"10.1016\/j.xphs.2025.103792"},{"issue":"1","key":"11106_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s11033-023-09087-9","volume":"51","author":"M Katoueezadeh","year":"2024","unstructured":"Katoueezadeh M, Maleki P, Torabizadeh SA, Farsinejad A, Khalilabadi RM, Valandani HM et al (2024) Combinatorial targeting of telomerase and DNA-PK induces synergistic apoptotic effects against Pre-B acute lymphoblastic leukemia cells. Mol Biol Rep 51(1):163","journal-title":"Mol Biol Rep"},{"key":"11106_CR22","doi-asserted-by":"publisher","unstructured":"Ashoub MH, Amiri M, Fatemi A, Farsinejad A (2024) Evaluation of ferroptosis-based anti-leukemic activities of ZnO nanoparticles synthesized by a green route against Pre-B acute lymphoblastic leukemia cells (Nalm-6 and REH). Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36608","DOI":"10.1016\/j.heliyon.2024.e36608"},{"key":"11106_CR23","doi-asserted-by":"crossref","unstructured":"Ashoub MH, Amiri M, Razavi R, Dawi EA, Farsinejad A, Divsalar F et al (2023) Induction of ferroptosis cell death in acute promyelocytic leukemia cell lines (NB4 and HL-60) using hydrothermally synthesized ZnO NPs in the presence of black cardamom extract. Results Eng 20:101479","DOI":"10.1016\/j.rineng.2023.101479"},{"issue":"4","key":"11106_CR24","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1007\/s10528-023-10565-9","volume":"62","author":"F Yari","year":"2024","unstructured":"Yari F, Ashoub MH, Amirizadeh N, Nikougoftar M, valandani HM, Khalilabadi RM (2024) Differential expression of the hTERT gene in umbilical cord-derived mesenchymal stem cells cocultured with B cell precursor leukemia cell microparticles or CD41+\/CD61\u2009+\u2009platelet microparticles. Biochem Genet 62(4):2796\u20132809","journal-title":"Biochem Genet"},{"issue":"1","key":"11106_CR25","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1038\/s41598-025-85329-z","volume":"15","author":"MH Ashoub","year":"2025","unstructured":"Ashoub MH, Afgar A, Farsinejad A, Razavi R, Anvari S, Fatemi A (2025) siRNA-mediated inhibition of hTERT enhances the effects of curcumin in promoting cell death in precursor-B acute lymphoblastic leukemia cells: an in silico and in vitro study. Sci Rep 15(1):3083","journal-title":"Sci Rep"},{"key":"11106_CR26","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.3389\/fphar.2019.01614","volume":"10","author":"AS Choudhari","year":"2020","unstructured":"Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O (2020) Phytochemicals in cancer treatment: from preclinical studies to clinical practice. Front Pharmacol 10:1614","journal-title":"Front Pharmacol"},{"issue":"1","key":"11106_CR27","first-page":"1","volume":"4","author":"V Rahimi","year":"2019","unstructured":"Rahimi V, Hekmatimoghaddam S, Jebali A, Khalili Sadrabad E, Akrami Mohajeri F (2019) Chemical composition and antifungal activity of essential oil of Zataria multiflora. J Nutr Food Secur 4(1):1\u20136","journal-title":"J Nutr Food Secur"},{"key":"11106_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.125073","volume":"243","author":"N Torabiardekani","year":"2023","unstructured":"Torabiardekani N, Karami F, Khorram M, Zare A, Kamkar M, Zomorodian K et al (2023) Encapsulation of Zataria multiflora essential oil in Polyvinyl alcohol\/chitosan\/gelatin thermo-responsive hydrogel: synthesis, physico-chemical properties, and biological investigations. Int J Biol Macromol 243:125073","journal-title":"Int J Biol Macromol"},{"key":"11106_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.tifs.2021.08.023","volume":"116","author":"NB Rathod","year":"2021","unstructured":"Rathod NB, Kulawik P, Ozogul F, Regenstein JM, Ozogul Y (2021) Biological activity of plant-based carvacrol and thymol and their impact on human health and food quality. Trends Food Sci Technol 116:733\u2013748","journal-title":"Trends Food Sci Technol"},{"key":"11106_CR30","doi-asserted-by":"publisher","unstructured":"Chen H-h, Fong SY (2022) Carvacrol induces apoptosis in human breast cancer cells via Bcl-2\/CytC signaling pathway. Res Square https:\/\/doi.org\/10.21203\/rs.3.rs-2105532\/v1","DOI":"10.21203\/rs.3.rs-2105532\/v1"},{"key":"11106_CR31","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.2147\/DDDT.S254218","volume":"14","author":"Q Zeng","year":"2020","unstructured":"Zeng Q, Che Y, Zhang Y, Chen M, Guo Q, Zhang W (2020) Thymol isolated from thymus vulgaris L. inhibits colorectal cancer cell growth and metastasis by suppressing the Wnt\/\u03b2-catenin pathway. Drug Des Devel Ther 14:2535\u20132547","journal-title":"Drug Des Devel Ther"},{"key":"11106_CR32","first-page":"879","volume":"80","author":"S Baginska","year":"2023","unstructured":"Baginska S, Golonko A, Swislocka R, Lewandowski W (2023) Monoterpenes as medicinal agents: exploring the pharmaceutical potential of p-cymene, p-cymenene, and \u03b3-terpinene. Acta Pol Pharm-Drug Res 80:879\u2013892","journal-title":"Acta Pol Pharm-Drug Res"},{"issue":"8","key":"11106_CR33","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3390\/ph16081086","volume":"16","author":"F Mohamed Abdoul-Latif","year":"2023","unstructured":"Mohamed Abdoul-Latif F, Ainane A, Houmed Aboubaker I, Mohamed J, Ainane T (2023) Exploring the potent anticancer activity of essential oils and their bioactive compounds: mechanisms and prospects for future cancer therapy. Pharmaceuticals 16(8):1086","journal-title":"Pharmaceuticals"},{"issue":"1","key":"11106_CR34","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s40360-021-00523-9","volume":"22","author":"A Valizadeh","year":"2021","unstructured":"Valizadeh A, Khaleghi AA, Roozitalab G, Osanloo M (2021) High anticancer efficacy of solid lipid nanoparticles containing Zataria multiflora essential oil against breast cancer and melanoma cell lines. BMC Pharmacol Toxicol 22(1):52","journal-title":"BMC Pharmacol Toxicol"},{"issue":"24","key":"11106_CR35","doi-asserted-by":"publisher","first-page":"6535","DOI":"10.1158\/1078-0432.CCR-20-0863","volume":"26","author":"SB Balachander","year":"2020","unstructured":"Balachander SB, Criscione SW, Byth KF, Cidado J, Adam A, Lewis P et al (2020) AZD4320, a dual inhibitor of Bcl-2 and Bcl-xL, induces tumor regression in hematologic cancer models without dose-limiting thrombocytopenia. Clin Cancer Res 26(24):6535\u20136549","journal-title":"Clin Cancer Res"},{"key":"11106_CR36","first-page":"100756","volume":"22","author":"SFA Rahman","year":"2020","unstructured":"Rahman SFA, Muniandy K, Soo YK, Tiew EYH, Tan KX, Bates TE et al (2020) Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines. Biochem Biophys Rep 22:100756","journal-title":"Biochem Biophys Rep"},{"key":"11106_CR37","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1016\/S2152-2650(22)01493-8","volume":"22","author":"H Ababneh","year":"2022","unstructured":"Ababneh H, Frigault M, Patel C (2022) ABCL-044 clinical outcomes of commercial CD19-targeted CAR t-cell therapy in patients with secondary central nervous system lymphoma. Clin Lymphoma Myeloma Leuk 22:S355","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"11106_CR38","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","volume":"11","author":"VA Pullarkat","year":"2021","unstructured":"Pullarkat VA, Lacayo NJ, Jabbour E, Rubnitz JE, Bajel A, Laetsch TW et al (2021) Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma. Cancer Discov 11(6):1440\u20131453","journal-title":"Cancer Discov"},{"issue":"7","key":"11106_CR39","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/07357907.2019.1651328","volume":"37","author":"N Riyahi","year":"2019","unstructured":"Riyahi N, Safaroghli-Azar A, Sheikh-Zeineddini N, Sayyadi M, Bashash D (2019) Synergistic effects of PI3K and c-Myc co-targeting in acute leukemia: shedding new light on resistance to selective PI3K-\u03b4 inhibitor CAL-101. Cancer Invest 37(7):311\u2013324","journal-title":"Cancer Invest"},{"issue":"1","key":"11106_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12288-021-01434-9","volume":"38","author":"R Shiri Heris","year":"2022","unstructured":"Shiri Heris R, Pourbagheri-Sigaroodi A, Yousefi A-M, Bashash D (2022) The superior cytotoxicity of dual targeting of BCR\/ABL and PI3K in K562 cells: proposing a novel therapeutic potential for the treatment of CML. Indian J Hematol Blood Transfus 38(1):51\u201360","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"5","key":"11106_CR41","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1007\/s12185-021-03126-6","volume":"113","author":"H Lee","year":"2021","unstructured":"Lee H, Basso IN, Kim DDH (2021) Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol 113(5):632\u2013641","journal-title":"Int J Hematol"},{"issue":"5","key":"11106_CR42","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41375-024-02229-3","volume":"38","author":"H Kantarjian","year":"2024","unstructured":"Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A et al (2024) Are there new relevant therapeutic endpoints in the modern era of the BCR:: ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia 38(5):947\u2013950","journal-title":"Leukemia"},{"key":"11106_CR43","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S253367","author":"X Chen","year":"2020","unstructured":"Chen X, Huang Z, Wu W, Xia R (2020) Inhibition of Skp2 sensitizes chronic myeloid leukemia cells to Imatinib. Cancer Manag Res. https:\/\/doi.org\/10.2147\/CMAR.S253367","journal-title":"Cancer Manag Res"},{"issue":"7","key":"11106_CR44","doi-asserted-by":"publisher","first-page":"719","DOI":"10.3390\/genes11070719","volume":"11","author":"N Fusco","year":"2020","unstructured":"Fusco N, Sajjadi E, Venetis K, Gaudioso G, Lopez G, Corti C et al (2020) PTEN alterations and their role in cancer management: are we making headway on precision medicine? Genes 11(7):719","journal-title":"Genes"},{"issue":"18","key":"11106_CR45","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.3390\/molecules25184210","volume":"25","author":"F Carofiglio","year":"2020","unstructured":"Carofiglio F, Trisciuzzi D, Gambacorta N, Leonetti F, Stefanachi A, Nicolotti O (2020) Bcr-Abl allosteric inhibitors: where we are and where we are going to. Molecules 25(18):4210","journal-title":"Molecules"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11106-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11106-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,28]],"date-time":"2025-12-28T05:05:22Z","timestamp":1766898322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11106-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11106"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11106-w","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no potential conflict of interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Kerman University of Medical Sciences Research Committee; ethical code: IR.KMU.REC.1400.250. All experiments were performed in accordance with relevant guidelines and regulations. Also, informed consent was obtained from all subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"1027"}}